Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00050348.xml
Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2005; 26(02): 49-50
DOI: 10.1055/s-0041-1733126
DOI: 10.1055/s-0041-1733126
Letter to the Editor
Objective Response with Geftinib in Non small cell Lung Cancer
Publication History
Article published online:
28 March 2022
© 2005. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Schiller J H, Harrington D, Belani C P, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl. J Med. 2003;346-:92-98.
- 2 Fukuoka M, Yano S, Giaccone G et al; Multi-institutional randomized phase II trial of Geftinib for previously treated patients with advanced non-small cell lung cancer. J. Clin oncol 2003;21-2237-46.
- 3 Kris M G, Natale R B, Herbst R S et al: Efficacy of Geftinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in the symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-58.
- 4 Haringhuizen A, Tinteron H, Vaessen H et al: Geftinib as a last treatment option for non-small cell lung cancer: durable disease control in a subset of patients. Annals Oncology 2004;15:786-792.